Stocks To Watch Today: L&T, Biocon, Titan, Kalyan Jewellers, Britannia, Union Bank NDTV Profit Research NDTV Profit

Big names like Lupin Ltd. Mahindra & Mahindra Financial Services Ltd. and Brigade Enterprises Ltd. among others are set to see action going into trade on Friday.

• Lupin: The company has received USFDA approval for Raltegravir tablets. Raltegravir tablets are used to treat HIV-1 infection in adults. US market size estimated at $34 million (IQVIA MAT March 2025. 

• Mahindra and Mahindra Financial Services: The company has approved the rights issue of Rs 194 per share for an aggregate amount of up to Rs 2,996 crore. The record date for determining the eligible shareholders is May 14. The rights issue will open for subscription on May 22 and close on June 6.

• Brigade Enterprises: The company will develop a premium commercial project with a gross development of over Rs 2,000 crore in Bengaluru.

• Tata Motors: The National Company Law Tribunal has approved the merger of Tata Motors Finance with the company, making Tata Motors Finance no longer a step-down subsidiary.

• Infosys: In-tech Automotive Engineering voluntarily dissolves its Mexican subsidiary.

• Bharat Petroleum Corp: The company has been awarded contracts for the development of 100 MW wind farm projects — 50 MW each in the states of Madhya Pradesh and Maharashtra. This initiative is a major step in BPCL’s strategy to transition to renewable energy and reduce reliance on imported fossil-based power.

• Oil & Natural Gas Corp: The company’s contract with BP as the technical service provider for the Mumbai High field remains in effect, as clarified in reports confirming that the Mumbai High tender has not been canceled despite uncertainties regarding the BP partnership.

• Gensol Engineering: SEBI has informed the company about the appointment of a Forensic Accountant and Investigator to carry out a forensic audit of its financial statements for the financial years ended March 31, 2022, 2023, 2024, and 2025 (review period).

• Birla Corp: The company has approved capital expenditure for capacity expansion, including the establishment of a 3.70 MTPA manufacturing unit in Madhya Pradesh and the development of two Greenfield Grinding Units in Uttar Pradesh, with a combined capacity of 3.40 MTPA.

• Zydus Lifesciences: has received final approval from the US Food And Drug Administration for its Glatiramer Acetate Injection. This medication is used to treat relapsing forms of multiple sclerosis.

• Reliance Industries: The company has announced that its step-down subsidiary, skyTran Inc, has initiated a voluntary dissolution.

Earnings Post Market Hours

L&T Q4FY25 Highlights (Consolidated, YoY)

• Revenue up 10.9% to Rs 74,392.28 crore versus Rs 67,078.68 crore (Bloomberg estimate: 76,298 crore).

• Ebitda up 13.4% to Rs 8,202.63 crore versus Rs 7,234.18 crore (Bloomberg estimate: 8301.3 crore).

• Margin at 11% versus 10.8% (Bloomberg estimate: 10.9%).

• Net Profit up 25.0% to Rs 5,497.26 crore versus Rs 4,396.12 crore (Bloomberg estimate: 4,545 crore).

REC Q4FY25 Highlights (Consolidated, YoY)

• Total Income up 20.8% to Rs 15,348 crore versus Rs 12,707 crore.

• NII up 37.58% at Rs 5879 crore versus Rs 4273 crore.

• GNPA at 1.35% versus 1.95% (QoQ).

• NNPA at 0.38% versus 0.74% (QoQ).

• Net profit up 5.7% to Rs 4,310 crore versus Rs 4,079 crore.

• NIMs have improved slightly, positively for us.

• Expect to continue runrate of 12% growth in FY25.

EPL Q4FY25 Highlights (Consolidated, YoY)

• Revenue up 7.4% to Rs 1,105 crore, compared to Rs 1,029 crore.

• Ebitda up 19.4% to Rs 228 crore compared to Rs 191 crore.

• Margin at 20.6%, compared to the previous 18.5%.

• Net Profit at Rs 114 crore, compared to Rs 22.3 crore.

• One-time Loss: Significantly reduced to Rs 3.6 crore, compared to Rs 60.5 crore in the previous year.

Biocon Q4FY25 Results Highlights (Consolidated, YoY)

• Revenue up 12.8% to Rs 4,417 crore versus Rs 3,917 crore (Bloomberg estimate: Rs 4,133 crore).

• Ebitda up 17.7% to Rs 1,078 crore versus Rs 916 crore (Bloomberg estimate: Rs 933 crore).

• Margin at 24.4% versus 23.4% (Bloomberg estimate: 22.6%).

• Net profit up 154.8% to Rs 344 crore versus Rs 135 crore (Bloomberg estimate: Rs 197.9 crore).

• Generics business delivered 46% YoY and a robust 53% sequential growth in Q4, concluding FY25 with an overall 8% growth over the previous year.

• Biocon Biologics continued its growth momentum in Q4, a robust 9% year-on-year revenue driven by significant market share gains in the U.S. and key tender wins in Emerging Markets.

 Titan Q4FY25 Results Highlights (Consolidated, YoY)

• Revenue up 19.4% to Rs 14,916 crore versus Rs 12,494 crore (Bloomberg estimate: Rs 13,693 crore).

• Ebitda up 29.1% to Rs 1,537 crore versus Rs 1,191 crore (Bloomberg estimate: Rs 1,353.8 crore).

• Margin at 10.3% versus 9.5% (Bloomberg estimate: 9.9%).

• Net Profit up 13% to Rs 871 crore versus Rs 771 crore (Bloomberg estimate: Rs 855 crore).

Kalyan Jewellers Q4FY25 Highlights (Consolidated, YoY)

• Revenue up 36.6% to Rs 6,181 crore versus Rs 4,525 crore. (Bloomberg estimate: Rs 6,167.7 crore).

• Ebitda up 34.8% to Rs 399 crore versus Rs 296 crore.

• Margin at 6.4% versus 6.5%.

• Net profit up 36.2% to Rs 188 crore versus Rs 138 crore. (Bloomberg estimate: Rs 185.8 crore)

Jindal Stainless Q4FY25 Highlights (Consolidated, YoY)

• Revenue up 8% to Rs 10,198 crore versus Rs 9,454 crore. (Bloomberg estimate: 10,568 crore).

• Ebitda up 2.5% to Rs 1,061 crore versus Rs 1,035 crore. (Bloomberg estimate: 1,091.6 crore).

• Margin at 10.4% versus 11%. (Bloomberg estimate: 10.3%).

• Net profit up 18% to Rs 591 crore versus Rs 501 crore. (Bloomberg estimate: 526 crore).

Pidilite Industries Q4FY25 Highlights (Consolidated, YoY)

• Revenue up 8.2% to Rs 3,141 crore versus Rs 2,902 crore.

• Ebitda up 9.6% to Rs 632.5 crore versus Rs 577 crore.

• Ebitda margin at 20.1% versus 19.8%.

• Net profit up 40.5% to Rs 422.3 crore versus Rs 300.6 crore.

IIFL Finance Ltd. Q4FY25 Highlights (Standalone, YoY)

• Total Income down 18.4% to Rs 1,140.68 crore versus Rs 1,398.12 crore.

• NII down 29.76% at Rs 517 crore versus Rs 736 crore.

• GNPA at 2.23% versus 2.42% (QoQ).

• NNPA at 1.05% versus 1.01% (QoQ).

• Net profit down 76.9% to Rs 38.42 crore versus Rs 165.03 crore.

Muthoot Microfin Q4FY25 Highlights (YoY)

• Total Income down 13.8% at Rs 556 crore versus Rs 645 crore (YoY).

• Net Loss of Rs 401 crore versus profit of Rs 120 crore (YoY).

• GNPA at 4.84% versus 3.03% (QoQ).

• NNPA at 1.34% versus 1.27% (QoQ).

Dilip Buildcon Q4FY25 (Consolidated, YoY)

• Revenue down 8% at Rs 3096 crore versus Rs 3365 crore.

• Ebitda up 100.91% at Rs 661 crore versus Rs 329 crore.

• Ebitda margin up 1157 bps at 21.35% versus 9.77%.

• Net profit up 10352.83% at Rs 277 crore versus Rs 2.65 crore.

Britannia Industries Q4FY25 Highlights (Consolidated, YoY)

• Revenue up 9% to Rs 4,432.19 crore versus Rs 4,069.36 crore (Bloomberg estimate: Rs 4,388.1 crore)

• Net Profit up 4% to Rs 560 crore versus Rs 538.28 crore (Bloomberg estimate: Rs 513.1 crore)

• Ebitda up 2.3% to Rs 805.17 crore versus Rs 787.45 crore (Bloomberg estimate: Rs 752.2 crore)

• Margin at 18.2% versus 19.4% (Bloomberg estimate: 17.1%)

Aarti Industries Q4FY25 Highlights (Consolidated, YoY)

• Revenue up 9.9% to Rs 1,949 crore versus Rs 1,773 crore (Bloomberg estimate: Rs 1,908.6 crore).

• Ebitda down 5.3% to Rs 268 crore versus Rs 283 crore (Bloomberg estimate: Rs 252.5 crore).

• Margin at 13.8% versus 16% (Bloomberg estimate: 13.2%).

• Net Profit down 27.3% to Rs 96 crore versus Rs 132 crore (Bloomberg estimate: Rs 66.8 crore).

Zee Entertainment Q4FY25 Highlights (Consolidated, YoY)

• Revenue up 0.7% to Rs 2,184 crore versus Rs 2,169.6 crore.

• Ebitda up 41.6% at Rs 298 crore versus Rs 210 crore.

• Margin at 13.6% versus 9.9%.

• Net Profit Rs 188.4 crore versus Rs 13.4 crore.

R Systems Q4FY25 Results Highlights (Consolidated, YoY)

• Revenue up 6.19% at Rs 442.4 crore versus Rs 416.6 crore.

• Net profit up 40.51% at Rs 38.5 crore versus Rs 27.4 crore.

• Ebitda up 32.33% at Rs 70.4 crore versus Rs 53.2 crore.

• Margin at 15.91% versus 12.77%.

Q4 Earnings – Rain Industries (Consolidated, YoY)

• Revenue up 2.7% at Rs 3,768 crore versus Rs 3,670 crore.

• Ebitda up 11.2% at Rs 380 crore verus Rs 342 crore.

• Margin at 10% vs 9.3%.

• Net loss of Rs 138 crore versus loss of Rs 146 crore.

Fine Organics Q4FY25 Results Highlights (Consolidated, YoY)

• Revenue up 11% at Rs 607 crore versus Rs 547 crore.

• Ebitda down 16.7% at Rs 119 crore versus Rs 144 crore.

• Margin at 19.7% versus 26.2%.

• Net profit down 15% at Rs 97 crore versus Rs 114 crore.

Union Bank of India Q4FY25 Highlights (Standalone, YoY)

• Net profit up 50.6% at Rs 4,985 crore versus Rs 3,310 crore.

• Net Interest Income up 1% at 9,514 crore versus Rs 9,437 crore.

• Gross NPA at 3.6% versus 3.85% (QoQ).

• Net NPA at 0.63% versus 0.82% (QoQ).

• Operating profit up 17.9% at Rs 7,700 crore versus Rs 6,533 crore.

• Provisions up 22.6% at Rs 1,544 crore versus Rs 1,260 crore.

• Provisions down 3.4% at Rs 1,544 crore versus Rs 1,599 crore.

Earnings In Focus

ABB India, Alkyl Amines Chemicals, Aditya Vision, Bank of India, Birla Corporation, Cera Sanitaryware, Cholamandalam Financial Holdings, Dr Reddys Laboratories, Eveready Industries India, Great Eastern Shipping Company, Grindwell Norton, India Shelter Finance Corporation, Intellect Design Arena, Jupiter Life Line Hospitals, Kirloskar Ferrous Industries, K.P.R. Mill, Lloyds Enterprises, Manappuram Finance, C.E. Info Systems, Motherson Sumi Wiring India, Navin Fluorine International, Novartis India, PTC India Financial Services, Relaxo Footwears, Reliance Power, Shakti Pumps India, Shyam Metalics and Energy, Swiggy, Thermax.

. Read more on Markets by NDTV Profit.The company that are lined up to post their fourth quarter results include ABB India, Alkyl Amines Chemicals, Aditya Vision, Bank of India.  Read MoreMarkets, Notifications 

​NDTV Profit